Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants (NCT04964271) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Italy60 participantsStarted 2021-09-09
Plain-language summary
This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participant is willing and able to give and sign a written informed consent for participation in the study
* Male, aged 18 years or above
* Diagnosed with prostate cancer at low or high risk
* Candidate to active surveillance (in case of low-risk disease) or treatment with curative intent such as radical prostatectomy or radiation therapy (in case of low risk patients not willing to undergo active surveillance or patients with high risk disease)
* Healthy participants undergoing a visit at the site for reason other than cancer diagnosis (including prostate cancer)
Exclusion Criteria:
* History of other malignancies other than prostate cancer (for healthy participants includes also prostate cancer)
* Undergone surgery or treatment for prostate cancer before enrolment
* Presence of known severe coagulation or haematological disorder
* Absence of written signed informed consent for participation in the study
What they're measuring
1
Number of commercial Antibodies capable of identify specific Prostate Cancer Biomarkers